Debasish Sundi

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 6

Top Topics

Regulatory T Cells

Prognostic Factors

Prostate Cancer

Radical Prostatectomy

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Science immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Keyan Salari, Debasish Sundi, Jason J Lee, Shu-Lin Wu, Chin-Lee Wu, Gabrielle DiFiore, Q Robert Yan, Andrew Pienkny, Chi K Lee, Daniel Oberlin, Greg Barme, Joel Piser, Robert Kahn, Edward Collins, Kevin G Phillips, Vincent M Caruso, Mahdi Goudarzi, Monica Garcia-Ransom, Peter S Lentz, Martha E Evans-Holm, Andrew R MacBride, Daniel S Fischer, Iden J Haddadzadeh, Brian C Mazzarella, Joe W Gray, Theresa M Koppie, Vincent T Bicocca, Trevor G Levin, Yair Lotan, Adam S Feldman
Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Danyal Daneshdoust, Ming Yin, Mingjue Luo, Debasish Sundi, Yongjun Dang, Cheryl Lee, Jenny Li, Xuefeng Liu
Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation. Cells 12 (13) (2023)
Hyunwoo Kwon, Johanna M Schafer, No-Joon Song, Satoshi Kaneko, Anqi Li, Tong Xiao, Anjun Ma, Carter Allen, Komal Das, Lei Zhou, Brian Riesenberg, Yuzhou Chang, Payton Weltge, Maria Velegraki, David Y Oh, Lawrence Fong, Qin Ma, Debasish Sundi, Dongjun Chung, Xue Li, Zihai Li
Androgen conspires with the CD8 + T cell exhaustion program and contributes to sex bias in cancer. Science immunology 7 (73) (2022)
Lamont J Wilkins, Jeffrey J Tosoian, Chad A Reichard, Debasish Sundi, Weranja K B Ranasinghe, Ridwan Alam, Zeyad Schwen, Chandana Reddy, Mohammed Allaf, John W Davis, Brian F Chapin, Ashley E Ross, Eric A Klein, Yaw A Nyame
Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. Cancer 127 (9) (2021)
Devin Plote, Woonyoung Choi, Sharada Mokkapati, Debasish Sundi, James E Ferguson, Jon Duplisea, Nigel R Parker, Seppo Yla-Herttuala, Suo Ctc Bladder Committee, David McConkey, Kimberly S Schluns, Colin P N Dinney
Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. Oncoimmunology 8 (5) (2019)
Debasish Sundi, Jeffrey J Tosoian, Yaw A Nyame, Ridwan Alam, Mary Achim, Chad A Reichard, Jianbo Li, Lamont Wilkins, Zeyad Schwen, Misop Han, John W Davis, Eric A Klein, Edward M Schaeffer, Andrew J Stephenson, Ashley E Ross, Brian F Chapin
Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer 125 (3) (2018)